Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort
Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort
复制标题
利妥昔单抗治疗中国队列中的无反应特发性膜性肾病。
DOI：
10.1093/ndt/gfx295
复制
发表时间：
2018-09-01
影响因子：
6.1
通讯作者：
Zhao, Ming-Hui
中科院分区：
文献类型：
--
作者：
Wang, Xin;Cui, Zhao;Zhao, Ming-Hui
Background. Rituximab had been shown to be effective in inducing remission of nephrotic syndrome in patients with idiopathic membranous nephropathy (iMN). This study applied rituximab therapy for 36 non-responsive iMN patients to investigate its effects and safety.Methods. Thirty-six iMN patients who were non-responsive to prior immunosuppression were enrolled. Rituximab was used for B-cell depletion in patients, with a goal of
